SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : BJCT-BIOJECT-needle less injection product
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Marc Kahn who wrote (420)1/5/2000 5:39:00 PM
From: geewiz   of 534
 
Hello Marc,

and best for you in the new year too; and I am always hopefully for our company! Thanks for your insights to the different Vical trials; I am lucky to remember the partner companies, forget the drugs! So the internal biojector is in development - that's really going to give us a less invasive market potential. It will also catapult us into the two highest revenue sectors of health care, cardiovascular and oncology. Imagine if we can experience assimilation to cardiology similar to what the stent makers did!!

On another topic, have you been following the NIH investigation into the death of Jesse Gelsinger? From a November 26th 1999 Wall St:

The December meeting of the NIH Recombinant DNA Advisory Committee is sure to be among the most significant ever. The committee will grapple with why Mr. Gelsinger died from the treatment when others didn't and whether he should have been part of the experiment at all. They will also explore whether numerous other human trials involving similar gene-delivery methods are safe.

At issue is a particular type of virus, adenovirus, which is often used as a vehicle to insert new genes into the body in an attempt to repair a genetic defect or to treat diseases such as cancer. In Mr. Gelsinger's case, a high dose of adenovirus conveying new genes was delivered directly into a main blood vessel in his liver; four days later he died.

James Wilson, research scientist who heads the U of Penn's Institute for Human Gene Therapy says "we should be extremely cautious about conducting any gene-therapy trial in which adenovirus is injected into the bloodstream".

Copywrite WSJ 11/26/99

This sounds positive for use of our platform, not just for naked DNA vaccines. Any thoughts?

later art
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News